Additional file 7 of Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer

Supplementary Material 7: Additional file 7.xlsx– Summary of variants for patients with anLRP1B-variant: Presents a list of patients with an LRP1B-variant together with other variants classified as pathogenic, likely pathogenic, VUS + + or VUS+. One column presents the patient’s clinical response to treatment. Abbreviations used: VUS = variant of unknown significance.